167 related articles for article (PubMed ID: 35392146)
1. METTL3 Accelerates Breast Cancer Progression via Regulating EZH2 m
Hu S; Song Y; Zhou Y; Jiao Y; Li G
J Healthc Eng; 2022; 2022():5794422. PubMed ID: 35392146
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA.
Chen WW; Qi JW; Hang Y; Wu JX; Zhou XX; Chen JZ; Wang J; Wang HH
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4263-4270. PubMed ID: 32373962
[TBL] [Abstract][Full Text] [Related]
3. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
Meng QZ; Cong CH; Li XJ; Zhu F; Zhao X; Chen FW
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4328-4336. PubMed ID: 32373970
[TBL] [Abstract][Full Text] [Related]
4. The m6A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m6A modification on SOX2.
Xie J; Ba J; Zhang M; Wan Y; Jin Z; Yao Y
J BUON; 2021; 26(2):444-449. PubMed ID: 34076991
[TBL] [Abstract][Full Text] [Related]
5. The m6A methyltransferase METTL3 aggravates the progression of nasopharyngeal carcinoma through inducing EMT by m6A-modified Snail mRNA.
Yu X; Zhao H; Cao Z
Minerva Med; 2022 Apr; 113(2):309-314. PubMed ID: 32512975
[TBL] [Abstract][Full Text] [Related]
6. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G
Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270
[TBL] [Abstract][Full Text] [Related]
7. m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1.
Ma XX; Cao ZG; Zhao SL
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3565-3571. PubMed ID: 32329830
[TBL] [Abstract][Full Text] [Related]
8. m
Chen J; Zhang YC; Huang C; Shen H; Sun B; Cheng X; Zhang YJ; Yang YG; Shu Q; Yang Y; Li X
Genomics Proteomics Bioinformatics; 2019 Apr; 17(2):154-168. PubMed ID: 31154015
[TBL] [Abstract][Full Text] [Related]
9. HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer.
Chen WM; Chen WD; Jiang XM; Jia XF; Wang HM; Zhang QJ; Shu YQ; Zhao HB
World J Gastroenterol; 2017 Sep; 23(33):6100-6110. PubMed ID: 28970725
[TBL] [Abstract][Full Text] [Related]
10. METTL3 promotes inflammation and cell apoptosis in a pediatric pneumonia model by regulating EZH2.
Yang Y; Yang X; Wu Y; Fu M
Allergol Immunopathol (Madr); 2021; 49(5):49-56. PubMed ID: 34476922
[TBL] [Abstract][Full Text] [Related]
11. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
[TBL] [Abstract][Full Text] [Related]
12. lncRNA ZEB2-AS1 Aggravates Progression of Non-Small Cell Lung Carcinoma via Suppressing PTEN Level.
Chen X; Wang K
Med Sci Monit; 2019 Nov; 25():8363-8370. PubMed ID: 31695021
[TBL] [Abstract][Full Text] [Related]
13. m
Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
[TBL] [Abstract][Full Text] [Related]
14. METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
Ouyang D; Hong T; Fu M; Li Y; Zeng L; Chen Q; He H; Wen Y; Cheng Y; Zhou M; Zou Q; Yi W
Breast Cancer Res; 2023 Feb; 25(1):19. PubMed ID: 36765397
[TBL] [Abstract][Full Text] [Related]
15. MiRNA-221-5p promotes breast cancer progression by regulating E-cadherin expression.
Niu XY; Zhang ZQ; Ma PL
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6983-6990. PubMed ID: 31486498
[TBL] [Abstract][Full Text] [Related]
16. The m
Cheng M; Sheng L; Gao Q; Xiong Q; Zhang H; Wu M; Liang Y; Zhu F; Zhang Y; Zhang X; Yuan Q; Li Y
Oncogene; 2019 May; 38(19):3667-3680. PubMed ID: 30659266
[TBL] [Abstract][Full Text] [Related]
17. METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by epigenetically suppressing RRAS.
Chen JX; Chen DM; Wang D; Xiao Y; Zhu S; Xu XL
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36960869
[TBL] [Abstract][Full Text] [Related]
18. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer.
Li Z; Hou P; Fan D; Dong M; Ma M; Li H; Yao R; Li Y; Wang G; Geng P; Mihretab A; Liu D; Zhang Y; Huang B; Lu J
Cell Death Differ; 2017 Jan; 24(1):59-71. PubMed ID: 27716745
[TBL] [Abstract][Full Text] [Related]
19. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
[TBL] [Abstract][Full Text] [Related]
20. LncRNA H19 promotes epithelial mesenchymal transition and metastasis of esophageal cancer via STAT3/EZH2 axis.
Chen MJ; Deng J; Chen C; Hu W; Yuan YC; Xia ZK
Int J Biochem Cell Biol; 2019 Aug; 113():27-36. PubMed ID: 31102664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
